Tags

Type your tag names separated by a space and hit enter

Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.
Biomed Pharmacother. 2008 Jul-Aug; 62(6):373-7.BP

Abstract

An imbalance between pro-angiogenic and anti-angiogenic factors is hypothesized in the pathogenesis of ovarian cystic disease. The aim of the following study was to explore the possible role of free vascular endothelial growth factor receptor 1 (sVEGFR-1), a soluble regulator of vascular endothelial growth factor (VEGF) action, in ovarian cystoadenoma, endometriomata and cystoadenocarcinoma. Forty-eight women, of whom fourteen had ovarian serous cysts, twenty-eight had stage III-IV ovarian endometriomata, and six had stage IIIB-IIIC ovarian carcinoma, were included. Sampling of serum, peritoneal and ovarian cystic fluids and of tumor tissue was performed before, during and following surgery, respectively. Levels of VEGF and sVEGFR-1 were measured in serum, peritoneal and cystic fluid. VEGF and sVEGFR-1 expression was evaluated in tumor tissue. There were no differences in serum VEGF and sVEGFR-1 levels nor in VEGF/VEGFR-1 ratio between study groups. Peritoneal fluid VEGF levels were higher in cystoadenocarcinoma patients than in endometriosis and in cystoadenoma patients, while sVEGFR-1 peritoneal fluid concentrations were significantly higher only in endometriosis-affected women. VEGF/VEGFR-1 ratio was highest in the peritoneal fluid of cancer patients with respect to the other two groups of women. Cystic fluid VEGF and VEGFR-1 concentrations were higher in endometriomata and in cystoadenocarcinomas than in cystadenomas but the VEGF/VEGFR-1 ratio was highest in cancer patients. Western blot evidenced a marked expression of VEGF and soluble VEGFR-1 in endometriosis tissue with respect to benign cyst tissue but a lower expression of both molecules, contrary to that expected, in cancer tissue. In conclusion, all in all, our data indicate that an excess of local VEGF with respect to its soluble receptor VEGFR-1 may be a key factor in the onset and maintenance of pathological neo-angiogenesis in ovarian cyst formation.

Authors+Show Affiliations

Department of Reproductive Medicine and Child Development, Division of Obstetrics and Gynecology, University of Pisa, Via Roma 67, 56126 Pisa, Italy. g.artini@obgyn.med.unipi.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18037256

Citation

Artini, Paolo Giovanni, et al. "Vascular Endothelial Growth Factor and Its Soluble Receptor in Benign and Malignant Ovarian Tumors." Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, vol. 62, no. 6, 2008, pp. 373-7.
Artini PG, Ruggiero M, Monteleone P, et al. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors. Biomed Pharmacother. 2008;62(6):373-7.
Artini, P. G., Ruggiero, M., Monteleone, P., Carpi, A., Cristello, F., Cela, V., & Genazzani, A. R. (2008). Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 62(6), 373-7.
Artini PG, et al. Vascular Endothelial Growth Factor and Its Soluble Receptor in Benign and Malignant Ovarian Tumors. Biomed Pharmacother. 2008 Jul-Aug;62(6):373-7. PubMed PMID: 18037256.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors. AU - Artini,Paolo Giovanni, AU - Ruggiero,Maria, AU - Monteleone,Patrizia, AU - Carpi,Angelo, AU - Cristello,Francesca, AU - Cela,Vito, AU - Genazzani,Andrea Riccardo, Y1 - 2007/10/30/ PY - 2007/04/19/received PY - 2007/06/27/revised PY - 2007/10/02/accepted PY - 2007/11/27/pubmed PY - 2008/10/1/medline PY - 2007/11/27/entrez SP - 373 EP - 7 JF - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JO - Biomed. Pharmacother. VL - 62 IS - 6 N2 - An imbalance between pro-angiogenic and anti-angiogenic factors is hypothesized in the pathogenesis of ovarian cystic disease. The aim of the following study was to explore the possible role of free vascular endothelial growth factor receptor 1 (sVEGFR-1), a soluble regulator of vascular endothelial growth factor (VEGF) action, in ovarian cystoadenoma, endometriomata and cystoadenocarcinoma. Forty-eight women, of whom fourteen had ovarian serous cysts, twenty-eight had stage III-IV ovarian endometriomata, and six had stage IIIB-IIIC ovarian carcinoma, were included. Sampling of serum, peritoneal and ovarian cystic fluids and of tumor tissue was performed before, during and following surgery, respectively. Levels of VEGF and sVEGFR-1 were measured in serum, peritoneal and cystic fluid. VEGF and sVEGFR-1 expression was evaluated in tumor tissue. There were no differences in serum VEGF and sVEGFR-1 levels nor in VEGF/VEGFR-1 ratio between study groups. Peritoneal fluid VEGF levels were higher in cystoadenocarcinoma patients than in endometriosis and in cystoadenoma patients, while sVEGFR-1 peritoneal fluid concentrations were significantly higher only in endometriosis-affected women. VEGF/VEGFR-1 ratio was highest in the peritoneal fluid of cancer patients with respect to the other two groups of women. Cystic fluid VEGF and VEGFR-1 concentrations were higher in endometriomata and in cystoadenocarcinomas than in cystadenomas but the VEGF/VEGFR-1 ratio was highest in cancer patients. Western blot evidenced a marked expression of VEGF and soluble VEGFR-1 in endometriosis tissue with respect to benign cyst tissue but a lower expression of both molecules, contrary to that expected, in cancer tissue. In conclusion, all in all, our data indicate that an excess of local VEGF with respect to its soluble receptor VEGFR-1 may be a key factor in the onset and maintenance of pathological neo-angiogenesis in ovarian cyst formation. SN - 0753-3322 UR - https://www.unboundmedicine.com/medline/citation/18037256/Vascular_endothelial_growth_factor_and_its_soluble_receptor_in_benign_and_malignant_ovarian_tumors_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0753-3322(07)00212-0 DB - PRIME DP - Unbound Medicine ER -